.webp)
Renata PLC has delivered the first shipment of 250 mg Terbinafine tablets, worth £1,50,000, to the market in the United Kingdom. The product has been supplied directly from the manufacturer, which is based in Rajendrapur, Gazipur.
The Medicines and Healthcare Products Regulatory Agency (MHRA) of the UK has approved the facility under which the product will be commercialised.
Renata confirmed the information through a disclosure published on the Dhaka Stock Exchange (DSE) website on Wednesday.
Terbinafine, an allylamine antifungal, is widely used for the treatment of onychomycosis of the toenail or fingernail due to dermatophytes. This product is also available in Bangladesh under the brand name Terbimax.
Renata, through its subsidiary Renata (UK), entered the UK market in 2018. At present, several products are commercialised, with agreements in place with five distribution partners.
The company is engaged in the business of manufacturing, marketing and distributing medicines, nutritional products and vaccines for humans, along with veterinary medications.
The company started its operations in 1972 as Pfizer (Bangladesh) Limited. However, in 1993, Pfizer transferred ownership of its operations to local shareholders, and the company name was changed to Renata Limited.
The drug manufacturer was enlisted on the stock exchanges in 1979. Its stock price increased by 1.38 per cent to Tk 626.50 at DSE on Wednesday.
